Field lab assistants catch a bat of their internet as they accumulate specimens for their Nipah virus analysis within the Shuvarampur space of Faridpur, Bangladesh, September 14, 2021.
| Photo Credit: Reuters
Scientists on the University of Oxford within the U.Okay. have launched first-in-human vaccine trials for the deadly Nipah virus which impacts many Asian international locations, together with India.
(For high well being information of the day, subscribe to our e-newsletter Health Matters)
The trials of the ChAdOx1 NipahB vaccine, consisting of 51 folks aged 18 to 55, shall be led by the Oxford Vaccine Group.
Nipah virus is a devastating illness that may be deadly in round 75% of instances, the researchers mentioned. Outbreaks have occurred in international locations in Asia, together with Singapore, Malaysia, Bangladesh and India, with a current one in Kerala in September final 12 months, they mentioned.
Nipah virus is carried by fruit bats and may be transmitted by contact with contaminated animals (corresponding to pigs) or from person-to-person through shut contact, the based on the researchers.
The virus, which is recognised by the World Health Organization as a precedence illness requiring pressing analysis, belongs to the identical household of paramyxoviruses as extra well-known pathogens like measles, they mentioned.
Despite the first outbreaks of Nipah virus occurring 25 years in the past in Malaysia and Singapore, there are at the moment no accepted vaccines or remedies.
“Nipah virus was first identified in 1998, and yet 25 years on the global health community still has no approved vaccines or treatments for this devastating disease,” mentioned the trial’s Principal Investigator, Brian Angus, from the University of Oxford’s Nuffield Department of Medicine.
“Due to the high mortality rate and the nature of Nipah virus transmission, the disease is identified as a priority pandemic pathogen. This vaccine trial is an important milestone in identifying a solution that could prevent local outbreaks occurring, while also helping the world prepare for a future global pandemic,” Mr. Angus mentioned.
In-Kyu Yoon, performing govt director of vaccine analysis & growth at CEPI, funders of the trial, mentioned Nipah has epidemic potential, with its fruit bat hosts present in areas house to over two billion folks.
“This trial is a step forward in efforts to build a suite of tools to protect against this killer virus. Knowledge gained could also inform development of other Paramyxovirus countermeasures,” Mr. Yoon mentioned.
The vaccine makes use of the ChAdOx1 platform, the identical viral vector vaccine platform that was used for the Oxford/AstraZeneca COVID-19 vaccine, the researchers mentioned.
The mission will run over the subsequent 18 months, with additional trials anticipated to comply with in a Nipah-affected nation, they added.
